Market Overview

First Solar, Intermolecular Extend, Expand Licensing Deal

Related IMI
18 Biggest Mid-Day Losers For Friday
Mid-Afternoon Market Update: Celator Pharmaceuticals Surges On Phase 3 Trial Results For Vyxeos; Constellium Shares Slide
Related FSLR
Benzinga's Top Initiations
The Market In 5 Minutes: Earnings Season, Tesla, Twitter And The EpiPen
Can Chip ETFs Continue Sharp Ascent? (Investor's Business Daily)

Intermolecular, Inc. (Nasdaq: IMI) and First Solar, Inc. (Nasdaq: FSLR) today announced they have entered into a two-year collaboration and licensing agreement focused on further increases to the conversion efficiency of First Solar's cadmium telluride (CdTe) solar cell technology. Under the new collaborative development program, First Solar and Intermolecular researchers will work together to develop disruptive new approaches to increasing the performance of CdTe solar cell technology using Intermolecular's proprietary High Productivity Combinatorial (HPC™) platform. The program targets substantial gains in First Solar's module conversion efficiency beyond its previously announced roadmap.

Posted-In: News


Related Articles (FSLR + IMI)

View Comments and Join the Discussion!